17 research outputs found
The global response: How cities and provinces around the globe tackled Covid-19 outbreaks in 2021
Background: Tackling the spread of COVID-19 remains a crucial part of ending the pandemic. Its highly contagious nature and constant evolution coupled with a relative lack of immunity make the virus difficult to control. For this, various strategies have been proposed and adopted including limiting contact, social isolation, vaccination, contact tracing, etc. However, given the heterogeneity in the enforcement of these strategies and constant fluctuations in the strictness levels of these strategies, it becomes challenging to assess the true impact of these strategies in controlling the spread of COVID-19.Methods: In the present study, we evaluated various transmission control measures that were imposed in 10 global urban cities and provinces in 2021 Bangkok, Gauteng, Ho Chi Minh City, Jakarta, London, Manila City, New Delhi, New York City, Singapore, and Tokyo.Findings: Based on our analysis, we herein propose the population-level Swiss cheese model for the failures and pit-falls in various strategies that each of these cities and provinces had. Furthermore, whilst all the evaluated cities and provinces took a different personalized approach to managing the pandemic, what remained common was dynamic enforcement and monitoring of breaches of each barrier of protection. The measures taken to reinforce the barriers were adjusted continuously based on the evolving epidemiological situation.Interpretation: How an individual city or province handled the pandemic profoundly affected and determined how the entire country handled the pandemic since the chain of transmission needs to be broken at the very grassroot level to achieve nationwide control
Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial
Background
Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population.
Methods
AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921.
Findings
Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months.
Interpretation
Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke
Mapping 123 million neonatal, infant and child deaths between 2000 and 2017
Since 2000, many countries have achieved considerable success in improving child survival, but localized progress remains unclear. To inform efforts towards United Nations Sustainable Development Goal 3.2—to end preventable child deaths by 2030—we need consistently estimated data at the subnational level regarding child mortality rates and trends. Here we quantified, for the period 2000–2017, the subnational variation in mortality rates and number of deaths of neonates, infants and children under 5 years of age within 99 low- and middle-income countries using a geostatistical survival model. We estimated that 32% of children under 5 in these countries lived in districts that had attained rates of 25 or fewer child deaths per 1,000 live births by 2017, and that 58% of child deaths between 2000 and 2017 in these countries could have been averted in the absence of geographical inequality. This study enables the identification of high-mortality clusters, patterns of progress and geographical inequalities to inform appropriate investments and implementations that will help to improve the health of all populations
COUPLING OF MEMBRANE BIOREACTOR AND OZONATION FOR REMOVAL OF ANTIBIOTICS FROM HOSPITAL WASTEWATER
Antibiotic residues in the environment and their potential toxic effects have been considered as one of the emerging research area in the environmental field. Their continuous introduction in our environment may increase their negative impacts on human health.  In this study, the eliminations of antibiotic such as Norfloxacin (NOR), Ciprofloxacin (CIP), Ofloxacin (OFL) and Sulfamethoxazole (SMZ) in wastewater of hospital were processed by membrane bioreactor (MBR) coupled with ozonation process. In particular, the MBR was applied for the antibiotic removals followed by ozonation process as a post-treatment stage to create an adequate integration to enhance removal efficiency. Achieved results after MBR treatment showed that the removal efficiency of NOR, CIP, OFL and SMZ were 90 ± 4.0% , 83 ± 13% , 81 ± 13 % and  39 ± 6%, respectivley. In addition, those antibiotic matters were continously removed by ozonation process with the removal efficiency of 87±9.0% , 83±1.0% , 81±2.3% and 66±2.3% for NOR, CIP, OFL and SMZ, respectively. In summary, antibiotics could be basically limited by the combination of MBR and ozonation before discharging in aquatic environment
Preparation and Characterization of Polyamidoamine G2.0-Hematin as a Biocatalyst for Fabricating Catecholic Gelatin Hydrogel
In this study, we report that an enzyme-mimicking biocatalyst polyamidoamine (PAMAM) dendrimer G2.0-hematin (G2.0-He) was fabricated successfully. The chemical structure of G2.0-He was verified by 1H NMR and FT-IR spectroscopy. G2.0-He exhibited a size distribution from 11.6±1.7 nm to 12.5±2.9 nm and a zeta potential from 32.5 mV to 25.6 mV along with the enhancement of the hematin conjugation degree. The relative activity of G2.0-He was evaluated based on pyrogallol oxidation reactions at pH=7. The results showed that G2.0-He was more stable than horseradish peroxidase (HRP) enzyme in high H2O2 concentrations. The HRP-mimic ability of G2.0-He was also confirmed by the catalyzation when preparing catecholic gelatin hydrogels under mild conditions. Moreover, our results also revealed that these hydrogels performed with excellent cytocompatibility in an in vitro study and could be used as a potential scaffold for adhesion and proliferation of fibroblast cells. The obtained results indicated that G2.0-He is a suitable platform for altering the HRP enzyme in several biomedical applications
Pioneer Use of Antimalarial Transdermal Combination Therapy in Rodent Malaria Model
We have previously reported 1,2,6,7-tetraoxaspiro [7.11]nonadecane (N-89) as a promising antimalarial compound. In this study, we evaluated the effect of transdermal therapy (tdt) of N-89 in combination (tdct) with other antimalarials as an application for children. We prepared ointment formulas containing N-89 plus another antimalarial drug, specifically, mefloquine, pyrimethamine, or chloroquine. In a 4-day suppressive test, the ED50 values for N-89 alone or combined with either mefloquine, pyrimethamine, or chloroquine were 18, 3, 0.1, and 3 mg/kg, respectively. Interaction assays revealed that N-89 combination therapy showed a synergistic effect with mefloquine and pyrimethamine, but chloroquine provoked an antagonistic effect. Antimalarial activity and cure effect were compared for single-drug application and combination therapy. Low doses of tdct N-89 (35 mg/kg) combined with mefloquine (4 mg/kg) or pyrimethamine (1 mg/kg) gave an antimalarial effect but not a cure effect. In contrast, with high doses of N-89 (60 mg/kg) combined with mefloquine (8 mg/kg) or pyrimethamine (1 mg/kg), parasites disappeared on day 4 of treatment, and mice were completely cured without any parasite recurrence. Our results indicated that transdermal N-89 with mefloquine and pyrimethamine provides a promising antimalarial form for application to children
Burden and mortality of sepsis and septic shock at a high-volume, single-center in Vietnam: a retrospective study
Background: Sepsis and septic shock have high mortality rates and often require a prolonged hospital stay. Patient outcomes may vary according to multiple factors. We aim to determine the prevalence of antimicrobial resistance and factors associated with mortality and hospital stay.Methods: Clinical and microbiological data of patients with sepsis or septic shock were retrospectively collected for 15 months. Patients with negative blood cultures and patients that did not meet the SEPSIS 3 criteria were excluded.Results: We included 48 septic shock and 28 septic patients (mean APACHE II 20.32 ± 5.61 and mean SOFA 9.41 ± 3.17), with a mean age of 60.5 ± 16.8 years and 56.6% males. WBCs, neutrophils, INR, and fibrinogen levels were significantly associated with mortality. 59.5% of the cultured bacteria were gram-negative (most common E. coli) and 27.8% were gram-positive (most common S. aureus), while 7.6% were other types of bacteria and 5.1% were fungi. Resistance patterns to gram-negative were varying, and resistance to piperacillin/tazobactam, carbapenems, and aminoglycosides were from 60% to 100% (A. baumanii), while they were highly sensitive to Colistin. E. coli was also resistant to ceftriaxone (77.8%) and sulbactam/cefoperazone (44.4%). Resistance rates for Gram-positives were high, from 86% to 100% for oxacillin, while for vancomycin, teicoplanin, and linezolid, they were often low but arrived up to 42.8%. According to our logistic regression analysis, patients over 65 year-old and those who received corticosteroids had a significantly increased risk of in-hospital mortality (OR: 4.0; OR: 4.8).Conclusion: Sepsis still poses a significant threat to patients’ health, even when positive blood culture results allow the administration of specific antibiotic treatment
Proceedings of the 4th Conference on Language Teaching and Learning
This conference proceedings contains articles on the various research ideas of the academic community and practitioners presented at the 4th Conference on Language Teaching and Learning (LTAL-2022). LTAL2022 was organized by the Ho Chi Minh City University of Food Industry, Vietnam on June 19-20, 2022.
Conference Title: 4th Conference on Language Teaching and LearningConference Acronym: LTAL-2022Conference Date: 19-20 June 2022Conference Location: VietnamConference Organizers: Ho Chi Minh City University of Food Industry, Vietnam